Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEON KIRCIK

Allopathic & Osteopathic Physicians Dermatology

NPI
1760576599
CMS profile
171344
Location
LOUSIVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$398,455.32

241 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEON KIRCIK

NPI 1760576599 · CMS profile ID 171344

Allopathic & Osteopathic Physicians / Dermatology

LOUSIVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760576599?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEON KIRCIK, NPI 1760576599, CMS profile ID 171344. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760576599?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). LEON KIRCIK, NPI 1760576599, CMS profile ID 171344. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760576599?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
LEON KIRCIK, NPI 1760576599, CMS profile ID 171344, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 241 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1760576599?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

241 matching records · $398,455.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 241 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 241.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $3,738.0009/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826381261 CMS
Novartis Pharmaceuticals Corporation $2,280.0009/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812752845 CMS
Novartis Pharmaceuticals Corporation $86.4609/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812752863 CMS
UCB, Inc. $1,600.0009/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807426749 CMS
UCB, Inc. $2,130.0009/13/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845288281 CMS
Amgen Inc. $3,738.0009/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826381263 CMS
Lilly USA, LLC $2,450.0009/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818595781 CMS
Lilly USA, LLC $2,800.0009/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818657111 CMS
Taro Pharmaceuticals USA, Inc. $500.0009/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851408869 CMS
LEO Pharma Inc. $6,580.0009/09/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842215309 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $5,600.0009/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849558943 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $282.8009/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849558947 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $411.6009/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849558951 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $91.1809/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849558953 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $750.0009/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849558899 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $1,050.0009/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849559023 CMS
Almirall LLC $296.8409/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819696477 CMS
EPI Health, LLC $75.4708/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854625371 CMS
Almirall LLC $193.1008/25/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819696473 CMS
Almirall LLC $153.8508/25/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819696475 CMS
Almirall LLC $104.6508/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819696479 CMS
Lilly USA, LLC $22.6608/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818657109 CMS
LEO Pharma Inc. $24.8108/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842215297 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $4,200.0008/20/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849559005 CMS
PFIZER INC. $3,900.0008/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832935107 CMS
Almirall LLC $2,400.0008/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819696471 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,600.0008/18/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851903921 CMS
Almirall LLC $55.7308/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965162951 CMS
Novartis Pharmaceuticals Corporation $2,280.0008/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812752843 CMS
Almirall LLC $95.5508/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965162949 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $1,400.0008/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849559055 CMS
Incyte Corporation $93.5208/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835527445 CMS
LEO Pharma Inc. $17.8808/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842215287 CMS
UCB, Inc. $114.5808/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807390269 CMS
UCB, Inc. $53.6308/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807393743 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,600.0008/05/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851903963 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,200.0008/05/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851903965 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $64.1808/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851903969 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $260.1008/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849559001 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $315.0008/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849559009 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $26.9508/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849559014 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $46.0008/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849559017 CMS
Almirall LLC $420.8007/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819696465 CMS
Almirall LLC $490.0907/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819696467 CMS
Lilly USA, LLC $2,800.0007/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818657107 CMS
Lilly USA, LLC $2,800.0007/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818583789 CMS
Lilly USA, LLC $2,450.0007/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818595779 CMS
Lilly USA, LLC $423.0507/23/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818603929 CMS
Lilly USA, LLC $12.3007/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818627391 CMS
Lilly USA, LLC $840.3407/23/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818640003 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $665,759.50 499
PY2020 $360,680.79 207
PY2021 $398,455.32 241
PY2022 $792,497.93 547
PY2023 $765,455.31 591
PY2024 $840,010.44 484
PY2025 $655,021.90 547

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $64,240.70 2
PY2025 Principal investigator $650,441.82 71
PY2024 Recipient $331,871.61 14
PY2024 Principal investigator $993,759.40 303
PY2023 Recipient $361,872.20 8
PY2023 Principal investigator $611,255.57 264
PY2022 Recipient $355.00 2
PY2022 Principal investigator $354,096.53 54
PY2021 Recipient $147,270.27 8
PY2021 Principal investigator $540,488.16 81
PY2020 Recipient $313,697.33 9
PY2020 Principal investigator $1,160,244.93 110
PY2019 Recipient $109,851.67 9
PY2019 Principal investigator $1,195,018.99 104

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $11,964.41 12/22/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226112171
Principal investigator 1 Janssen Research & Development, LLC $5,907.00 12/15/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175412570
Principal investigator 1 Janssen Research & Development, LLC $6,249.00 12/15/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175412594
Principal investigator 1 SANOFI US SERVICES INC. $15,794.00 12/15/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112178
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,630.00 12/09/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289378
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 12/09/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289380
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,400.00 12/09/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289382
Principal investigator 1 SANOFI US SERVICES INC. $7,486.00 12/08/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112160
Principal investigator 1 SANOFI US SERVICES INC. $65,773.00 12/08/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226112167
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,045.60 12/01/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289029
Principal investigator 1 SANOFI US SERVICES INC. $19,500.43 11/17/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226112153
Principal investigator 1 SANOFI US SERVICES INC. $625.00 11/04/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226112147
Principal investigator 1 Janssen Research & Development, LLC $3,296.00 10/27/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175412544
Principal investigator 1 SANOFI US SERVICES INC. $7,937.00 10/27/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112140
Principal investigator 1 SANOFI US SERVICES INC. $9,726.68 10/14/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226112128
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 10/14/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112135
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,460.60 09/25/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285903
Principal investigator 1 Janssen Research & Development, LLC $6,592.00 09/22/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175412549
Principal investigator 1 SANOFI US SERVICES INC. $21,974.78 09/15/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226112117
Principal investigator 1 SANOFI US SERVICES INC. $8,314.00 09/08/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112123
Principal investigator 1 Janssen Research & Development, LLC $3,296.00 09/01/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175412600
Principal investigator 1 Incyte Corporation $2,500.00 08/15/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240591233
Principal investigator 1 SANOFI US SERVICES INC. $8,222.29 08/11/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226112104
Principal investigator 1 SANOFI US SERVICES INC. $23,256.00 08/11/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226112111
Principal investigator 1 SANOFI US SERVICES INC. $16,681.00 08/04/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112100
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,638.40 08/01/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283669
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,156.20 08/01/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283671
Recipient PFIZER INC. $3,200.00 07/31/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228802936
Principal investigator 1 Janssen Research & Development, LLC $8,062.00 07/28/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175412578
Principal investigator 1 SANOFI US SERVICES INC. $5,690.10 07/14/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226112082
Principal investigator 1 SANOFI US SERVICES INC. $4,818.00 07/14/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112090
Principal investigator 1 SANOFI US SERVICES INC. $6,820.32 07/14/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226112094
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,861.30 07/08/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282406
Principal investigator 1 Janssen Research & Development, LLC $11,941.00 06/30/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175412607
Principal investigator 1 SANOFI US SERVICES INC. $4,657.92 06/16/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226112054
Principal investigator 1 SANOFI US SERVICES INC. $4,405.40 06/16/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226112059
Principal investigator 1 SANOFI US SERVICES INC. $3,705.00 06/16/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112065
Principal investigator 1 SANOFI US SERVICES INC. $21,046.00 06/09/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226112047
Principal investigator 1 Janssen Research & Development, LLC $11,318.00 05/26/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175412564
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,945.05 05/20/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279974
Principal investigator 1 SANOFI US SERVICES INC. $3,337.00 05/19/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112072
Principal investigator 1 SANOFI US SERVICES INC. $10,567.13 05/19/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226112076
Principal investigator 1 SANOFI US SERVICES INC. $5,335.30 05/12/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226112037
Principal investigator 1 SANOFI US SERVICES INC. $22,539.00 05/05/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226112026
Principal investigator 1 Janssen Research & Development, LLC $4,858.00 04/28/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175412539
Principal investigator 1 Incyte Corporation $1,975.14 04/25/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240591229
Principal investigator 1 SANOFI US SERVICES INC. $5,080.00 04/14/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112019
Principal investigator 1 SANOFI US SERVICES INC. $8,802.61 04/07/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226112006
Principal investigator 1 SANOFI US SERVICES INC. $9,135.30 04/07/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226112015
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,996.80 04/03/2025 Non-covered Recipient Entity
Physicians Skin Care, PLLC
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) No dispute reported 06/30/2026 1235994676
Principal investigator 1 SANOFI US SERVICES INC. $3,836.00 04/02/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226111988
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 03/25/2025 Non-covered Recipient Entity
Skin Sciences PLLC Leon Kircik
Speso moderate to severe HS Phase IIb/III No dispute reported 06/30/2026 1220791725
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,550.00 03/25/2025 Non-covered Recipient Entity
Skin Sciences PLLC Leon Kircik
Speso moderate to severe HS Phase IIb/III No dispute reported 06/30/2026 1220791727
Principal investigator 1 Janssen Research & Development, LLC $16,765.00 03/24/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175412589
Principal investigator 1 SANOFI US SERVICES INC. $7,042.00 03/24/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226111983
Principal investigator 1 SANOFI US SERVICES INC. $7,813.83 03/17/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226112001
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,131.39 03/14/2025 Non-covered Recipient Entity
Skin Sciences, Pllc
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235993663
Principal investigator 1 SANOFI US SERVICES INC. $7,714.00 03/10/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226111994
Principal investigator 1 SANOFI US SERVICES INC. $25,563.00 03/04/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226111974
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,809.75 03/04/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275939
Principal investigator 1 Janssen Research & Development, LLC $21,737.00 03/03/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175412556
Principal investigator 1 SANOFI US SERVICES INC. $9,856.16 02/24/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226112012
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,425.00 02/21/2025 Non-covered Recipient Entity
Skin Sciences
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis No dispute reported 06/30/2026 1235993665
Principal investigator 1 Eli Lilly and Company $2,500.00 02/13/2025 Non-covered Recipient Entity
SKIN SCIENCES, PLLC
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187888270
Recipient LEO Pharma Inc. $61,040.70 02/06/2025 Covered Recipient Physician THE SAFETY AND EFFICACY OF ADBRY IN SKIN OF COLOR PATIENTS WITH ATOPIC DERMATITIS IN THE REAL-WORLD SETTING No dispute reported 06/30/2026 1251994450
Principal investigator 1 SANOFI US SERVICES INC. $29,942.82 02/04/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226111967
Principal investigator 1 Incyte Corporation $2,335.71 01/28/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 1240477124
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $173.06 01/27/2025 Non-covered Recipient Entity
Skin Sciences
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus No dispute reported 06/30/2026 1235993667
Principal investigator 1 Janssen Research & Development, LLC $25,777.00 01/27/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175412582
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,675.78 01/21/2025 Non-covered Recipient Entity
Skin Sciences
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus No dispute reported 06/30/2026 1235993669
Principal investigator 1 SANOFI US SERVICES INC. $4,860.00 01/21/2025 Non-covered Recipient Entity
Leon Kircik Md Skin Sciences Pllc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226111978
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,346.20 01/21/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274263
Principal investigator 1 Incyte Corporation $3,266.36 01/17/2025 Non-covered Recipient Entity
SKIN SCIENCES PLLC
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240591224